Press release from Companies
Published: 2017-08-14 08:03:13
WntResearch today announced that all patients have now finalized the treatment in the expansion group of a Phase 1b study with the drug candidate Foxy-5, developed to prevent metastases in patients with certain common types of cancer. Hence, the Phase 1b study is now completed and the company can continue the planning of a randomized Phase 2 study with Foxy-5.
Preliminary results from the dose-finding part of the study showed that Foxy-5 has a favorable safety profile and provides clear signals of biological effect. Based on these positive results, a dose level was selected for evaluation in a further few patients, who have now completed their treatment. The same dose level will be evaluated in an upcoming Phase 2 study.
"The completion of the Phase 1b study with Foxy-5 is an important milestone for WntResearch. With the completed clinical study as a basis, we can now proceed and plan for the continued development of our unique drug candidate against tumor spread," says Henrik Lawaetz, CEO of WntResearch AB.
The Phase 1b study was performed on patients with cancer in the colon, prostate or breast, for a three-week treatment period. In consultation with their physician, some patients chose to continue treatment for a few weeks after the formal study period ended. Foxy-5 showed a continued favorable safety profile in these patients.
"The successful completion of the Phase 1b study, and the recently announced positive preliminary results from a retrospective study, provide an excellent basis for optimizing the Phase 2 study design," commented Henrik Lawaetz, CEO of WntResearch AB.
For further information contact:
Henrik Lawaetz, CEO
Telephone: +46 72 702 4694
This information is information that WntResearch AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on August 14, 2017.
WntResearch is developing a new type of cancer treatment based on pioneering research, which shows that the endogenous protein Wnt-5a plays a crucial role for tumour cells' ability to relocate and spread in the body. Most patients that die of cancer do so not due to the primary tumour, but due to metastases. The need for a specific treatment to counteract metastasis is therefore in high demand.
WntResearch's most advanced drug candidate Foxy-5 has in preclinical tests been shown to reduce tumour cells' mobility and thereby counteract the occurrence of metastases. The results from a completed phase 1 study show a favourable safety and pharmacokinetic profile, as well as early indications of biological activity. A phase 1b study is currently ongoing in patients with cancer of the colon, prostate and breast. WntResearch is a public company listed at AktieTorget in Stockholm, Sweden.
For further information: www.wntresearch.com